553 related articles for article (PubMed ID: 22869884)
1. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Fischer K; Cramer P; Busch R; Böttcher S; Bahlo J; Schubert J; Pflüger KH; Schott S; Goede V; Isfort S; von Tresckow J; Fink AM; Bühler A; Winkler D; Kreuzer KA; Staib P; Ritgen M; Kneba M; Döhner H; Eichhorst BF; Hallek M; Stilgenbauer S; Wendtner CM
J Clin Oncol; 2012 Sep; 30(26):3209-16. PubMed ID: 22869884
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
[TBL] [Abstract][Full Text] [Related]
3. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.
Visco C; Finotto S; Pomponi F; Sartori R; Laveder F; Trentin L; Paolini R; Di Bona E; Ruggeri M; Rodeghiero F
Am J Hematol; 2013 Apr; 88(4):289-93. PubMed ID: 23450436
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Zaja F; Mian M; Volpetti S; Visco C; Sissa C; Nichele I; Castelli M; Ambrosetti A; Puglisi S; Fanin R; Cortelazzo S; Pizzolo G; Trentin L; Rodeghiero F; Paolini R; Vivaldi P; Sancetta R; Isola M; Semenzato G
Am J Hematol; 2013 Nov; 88(11):955-60. PubMed ID: 23861234
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.
Iannitto E; Morabito F; Mancuso S; Gentile M; Montanini A; Augello A; Bongarzoni V; D'Arco A; Di Renzo N; Fazzi R; Franco G; Marasca R; Mulè A; Musso M; Musto P; Pennese E; Piccin A; Rota-Scalabrini D; Visani G; Rigacci L
Br J Haematol; 2011 May; 153(3):351-7. PubMed ID: 21371003
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
Knauf WU; Lissichkov T; Aldaoud A; Liberati A; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Tremmel L; Merkle K; Montillo M
J Clin Oncol; 2009 Sep; 27(26):4378-84. PubMed ID: 19652068
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
Chow KU; Kim SZ; von Neuhoff N; Schlegelberger B; Stilgenbauer S; Wunderle L; Cordes HJ; Bergmann L
Eur J Haematol; 2011 Nov; 87(5):426-33. PubMed ID: 21749447
[TBL] [Abstract][Full Text] [Related]
9. Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial.
Molica S
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1333-40. PubMed ID: 21929307
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Fowler N; Kahl BS; Lee P; Matous JV; Cashen AF; Jacobs SA; Letzer J; Amin B; Williams ME; Smith S; Saleh A; Rosen P; Shi H; Parasuraman S; Cheson BD
J Clin Oncol; 2011 Sep; 29(25):3389-95. PubMed ID: 21810687
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Ohmachi K; Niitsu N; Uchida T; Kim SJ; Ando K; Takahashi N; Takahashi N; Uike N; Eom HS; Chae YS; Terauchi T; Tateishi U; Tatsumi M; Kim WS; Tobinai K; Suh C; Ogura M
J Clin Oncol; 2013 Jun; 31(17):2103-9. PubMed ID: 23650408
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.
Smolej L; Doubek M; Panovská A; Simkovič M; Brychtová Y; Belada D; Motyčková M; Mayer J
Leuk Res; 2012 Oct; 36(10):1278-82. PubMed ID: 22840362
[TBL] [Abstract][Full Text] [Related]
13. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
[TBL] [Abstract][Full Text] [Related]
15. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
16. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Barton JH; Houston GA; Hermann RC; Bradof JE; Greco FA;
J Clin Oncol; 2003 May; 21(9):1746-51. PubMed ID: 12721250
[TBL] [Abstract][Full Text] [Related]
17. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
[TBL] [Abstract][Full Text] [Related]
18. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab.
García Muñoz R; Izquierdo-Gil A; Muñoz A; Roldan-Galiacho V; Rabasa P; Panizo C
Ann Hematol; 2014 Nov; 93(11):1879-87. PubMed ID: 24951124
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine in the treatment of chronic lymphocytic leukemia.
Knauf W
Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
